圣诺生物：预计2025年净利润同比增加204.42%至280.53%

Core Viewpoint - The company expects to achieve a net profit attributable to shareholders of 152 million to 190 million yuan in 2025, representing an increase of 102 million to 140 million yuan compared to the previous year, with a year-on-year growth of 204.42% to 280.53% [1] Financial Performance - The projected net profit excluding non-recurring gains and losses for 2025 is estimated to be between 149 million and 186 million yuan, which indicates an increase of 103 million to 140 million yuan year-on-year, translating to a growth of 226.07% to 307.58% [1] Business Strategy - During the reporting period, the company focused on its annual operational strategy, advancing the implementation of its construction capacity while continuously expanding both domestic and international markets [1] - The demand for the company's peptide raw material business orders has been steadily increasing, contributing to a significant overall performance improvement compared to the previous year [1] Market Position - The substantial growth in performance further enhances the company's global competitiveness in the peptide pharmaceutical market [1]